title: [The trend of developing new disease-modifying drugs in Alzheimer's disease].
abstract: Development of symptomatic treatment of Alzheimer s disease by cholinesterase inhibitors like donepezil was successful. However, it is a disappointment that development of disease-modifying drugs such as anti-amyloid drug based on amyloid-cascade theory has been interrupted or unsuccessful. Therefore, we have to be more cautious regarding inclusion criteria for clinical trials of new drugs. We agree that potentially curative drugs should be started before symptoms begin as a preemptive therapy or prevention trial. The concept of personalized medicine also is important when ApoE4-related amyloid reducing therapy is considered. Unfortunately, Japanese-ADNI has suffered a setback since 2014. However, Ministry of Health, Labour and Welfare gave a final remark that there was nothing wrong in the data managing process in the J-ADNI data center. We should pay more attention to worldwide challenges of speeding up new drug development.
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Arai
authors.forename: Katsutoshi
authors.initials: K
authors.lastname: Furukawa
authors.forename: Naoki
authors.initials: N
authors.lastname: Tomita
authors.forename: Aiko
authors.initials: A
authors.lastname: Ishiki
authors.forename: Nobuyuki
authors.initials: N
authors.lastname: Okamura
authors.forename: Yukitsuka
authors.initials: Y
authors.lastname: Kudo
mesh_terms: D000375:Aging; D000544:Alzheimer Disease / Q000188:drug therapy*; D000682:Amyloid / Q000037:antagonists & inhibitors / Q000378:metabolism; D006801:Humans; D016875:tau Proteins / Q000378:metabolism
chemical_list: D000682:Amyloid; D016875:tau Proteins